Abstract: Disclosed is a reagent for preparing a cell sample, the reagent containing a solid support and a trapping substance that is linked to the solid support by a cleavable linker and traps a target cell. In the reagent for preparing a cell sample, a fluorescent dye is bound to a site on the linker closer to the trapping substance than the cleavage position in the linker, or a site on the trapping substance except for a binding site to the target cell in the trapping substance. The reagent for preparing a cell sample is useful for enriching a target cell using an antibody-modified solid support and subsequent staining for separating by a cell sorter, at the same time.

Abstract: Provided is a platelet aggregation capacity analyzer including a blood coagulation system-analyzing unit that analyzes a platelet aggregation capacity based on measurement data during a coagulation process of a platelet-containing sample, and an output control unit that controls an output of results analyzed by the blood coagulation system-analyzing unit, in which the blood coagulation system-analyzing unit analyzes the platelet aggregation capacity of the platelet-containing sample based on the barb of measurement data during the coagulation process with a platelet aggregation inhibitor added to the platelet-containing sample and measurement data during the coagulation process without a platelet agonist or the platelet aggregation inhibitor added to the platelet-containing sample.

Abstract: An object of the present technology is to provide a sample preparation system for increasing a content ratio of target cells. The present technology provides a sample preparation device including a container, and a channel in which a bioparticle-containing liquid flows, the channel accommodated in the container, in which the channel is formed such that a centrifugal force acts on the bioparticle-containing liquid, and an outer peripheral wall of the channel is formed such that at least part of components of the bioparticle-containing liquid may be transferred to an outside of the channel. Furthermore, the present technology also provides a sample preparation system including the sample preparation device, and an analysis device that executes analysis of the bioparticle-containing liquid that passes through the channel.

Abstract: An object of the present technology is to provide a sample preparation system for increasing the content percentage of target cells. The present technology provides a sample preparation system including a bioparticle-capturing module including a substrate to which a substance that captures bioparticles is fixed, a reservoir into which the bioparticles released from the substrate are recovered, and a hollow fiber membrane module through which the bioparticles in the reservoir are flowed. The present technology also provides a sample preparation method including a capturing step of capturing bioparticles with use of a substrate to which a substance that captures the bioparticles is fixed, a recovery step of recovering, into a reservoir, the bioparticles released from the substrate, and a hollow fiber membrane treatment step of causing the bioparticles recovered into the reservoir to flow through a hollow fiber membrane module.

Abstract: A measurement method of simply and quickly measuring platelet aggregation, is provided. The measurement method is a platelet aggregation analysis method, including: a step of adding a platelet-inducing substance and a calcium salt to a platelet-containing specimen; a step of stirring the platelet-containing specimen; and a step of acquiring measurement data of an electrical characteristic and/or viscoelasticity of the platelet-containing specimen.

Abstract: To provide a new technology for measuring the aggregation capacity of platelets. Provided is, for instance, a platelet aggregation capacity analyzer including a blood coagulation system-analyzing unit configured to analyze a platelet aggregation capacity on the basis of measurement data during a coagulation process of a platelet-containing sample, and an output control unit configured to control an output of results analyzed by the blood coagulation system-analyzing unit, in which the blood coagulation system-analyzing unit analyzes the platelet aggregation capacity of the platelet-containing sample on the basis of measurement data during a coagulation process with a platelet aggregation inhibitor added to the platelet-containing sample and measurement data during a coagulation process without a platelet agonist or the platelet aggregation inhibitor added to the platelet-containing sample.

Abstract: There is provided a blood-clotting-system analysis apparatus, including: a pair of electrodes; an application unit configured to apply alternating voltage to the pair of electrodes at predetermined time intervals; a measurement unit configured to measure a complex dielectric constant of a blood sample placed between the pair of electrodes; and an analysis unit configured to analyze, by using at least two or more types of blood clotting-related assays, activity of a clotting factor and activity of a clotting inhibition factor on a basis of a complex dielectric constant of a particular frequency in a predetermined time period measured at the time intervals after an anticoagulant effect acting on the blood sample is resolved.

Abstract: To provide a system capable of evaluating a deficiency and/or a lowered function of extrinsic coagulation factors or intrinsic coagulation factors with high sensitivity by adding new procedures and apparatuses to a blood coagulation system analysis procedure, an apparatus, or the like. A blood coagulation system analysis system includes a blood coagulation system measurement apparatus that performs blood coagulation system measurement of a blood sample; and a blood coagulation system analysis apparatus including a coagulation parameter extraction unit that extracts a coagulation parameter from a measurement result by the blood coagulation system measurement apparatus, and a blood coagulation evaluation unit that evaluates a level of blood coagulation of the blood sample on the basis of the coagulation parameter, the measurement by the blood coagulation system measurement apparatus being performed under an extrinsic system acceleration condition and an intrinsic system acceleration condition.

Abstract: Provided is a technique that allows high-accuracy electrical measurement without the influence of blood sedimentation in a case where various measurements or evaluations are performed using blood samples containing a blood cell component and a plasma component. Provided is an electrical measurement method for electrically measuring a blood sample including at least a blood cell component and a plasma component, the electrical measurement method including the step of adding a blood sedimentation inhibitor to the blood sample. Also provided is a blood sedimentation inhibitor for use in electrical measurement of a blood sample including at least a blood cell component and a plasma component, the blood sedimentation inhibitor including a non-cationic water-soluble compound and being capable of increasing specific gravity and/or viscosity of the plasma component.

Abstract: To provide a technology that allows for simple and highly accurate evaluation of the condition of blood. Provided is a blood condition analysis device, for analyzing the condition of a blood sample having added thereto at least one kind of drug selected from the group consisting of anticoagulation treatment cancelling agents, coagulation activators, anticoagulants, platelet activators, and antiplatelet agents, the device including a drug dosage control unit for controlling the dosage of the drug to be added to the blood sample on the basis of the hematocrit and/or hemoglobin content of the blood sample.

Abstract: To an electrical characteristic measuring device that further improves the accuracy of measurement of an electrical characteristic of a blood sample. Provided is an electrical characteristic measuring device including: a measuring unit configured to measure an electrical characteristic of a blood sample; and an alert generation unit configured to issue an alert signal when an erythrocyte sedimentation rate in the blood sample exceeds a prescribed standard during measurement of the blood sample.

Abstract: A measurement method of simply and quickly measuring platelet aggregation, is provided. The measurement method is a platelet aggregation analysis method, including: a step of adding a platelet-inducing substance and a calcium salt to a platelet-containing specimen; a step of stirring the platelet-containing specimen; and a step of acquiring measurement data of an electrical characteristic and/or viscoelasticity of the platelet-containing specimen.

Abstract: To provide a system capable of evaluating a deficiency and/or a lowered function of extrinsic coagulation factors or intrinsic coagulation factors with high sensitivity by adding new procedures and apparatuses to a blood coagulation system analysis procedure, an apparatus, or the like. A blood coagulation system analysis system includes a blood coagulation system measurement apparatus that performs blood coagulation system measurement of a blood sample; and a blood coagulation system analysis apparatus including a coagulation parameter extraction unit that extracts a coagulation parameter from a measurement result by the blood coagulation system measurement apparatus, and a blood coagulation evaluation unit that evaluates a level of blood coagulation of the blood sample on the basis of the coagulation parameter, the measurement by the blood coagulation system measurement apparatus being performed under an extrinsic system acceleration condition and an intrinsic system acceleration condition.

Abstract: A blood state analysis device (1) that analyzes a state of a blood sample, as used for clotting time testing, said blood sample comprising a plasma and at least one reagent, including a correction unit (11) configured to correct a measured blood coagulation evaluation result of the blood sample based on a relation between reference concentrations of the at least one reagent in plasma and reference blood coagulation evaluation results, the at least one reagent is an anticoagulation treatment releasing agent, a coagulation activator, an anticoagulant, a platelet activator, an antiplatelet drug, or a combination thereof and is present in the blood sample. For instance, such device (1) allows to correct blood clotting time results with respect to concentrations of an anti-coagulant drug present in the blood sample.

Abstract: There are provided a new device and a new method for measurement of platelet aggregability which can be used for monitoring in an anti-platelet therapy. A platelet aggregability analyzing device includes: a blood coagulation system analyzing section that analyzes platelet aggregability on the basis of measurement data on a coagulation process of a platelet-containing sample to which a platelet inducing substance has been added; and an output control section that controls output of a result of an analysis by the blood coagulation system analyzing section.

Abstract: To provide a technique which is useful in verification of measurement accuracy before measurement in the measurement of electric characteristics of a blood sample. There is provided a sample for measurement of electric characteristics at least including a liquid containing a blood coagulation factor, and micro particles. The density of each of the micro particles is different from the density of the liquid containing the blood coagulation factor. In addition, there is provided an electric characteristic measuring apparatus and an electric characteristic measuring method as well each using the sample for measurement of electric characteristics.

Abstract: Provided is a technique that allows high-accuracy electrical measurement without the influence of blood sedimentation in a case where various measurements or evaluations are performed using blood samples containing a blood cell component and a plasma component. Provided is an electrical measurement method for electrically measuring a blood sample including at least a blood cell component and a plasma component, the electrical measurement method including the step of adding a blood sedimentation inhibitor to the blood sample. Also provided is a blood sedimentation inhibitor for use in electrical measurement of a blood sample including at least a blood cell component and a plasma component, the blood sedimentation inhibitor including a non-cationic water-soluble compound and being capable of increasing specific gravity and/or viscosity of the plasma component.

Abstract: Provided is a technology useful for verifying measurement accuracy before measurement of an electrical characteristic of blood samples. A sample for use in electrical characteristic measurement is provided including erythrocytes incompletely fixed with a fixative, the fixed erythrocytes being such that an electrical characteristic of a mixture of the fixed erythrocytes and plasma components can change over time. An electrical characteristic measurement method is provided including measuring an electrical characteristic of the sample for use in electrical characteristic measurement over time before measuring an electrical characteristic of blood samples over time. An electrical characteristic measurement device is provided including a determination unit configured to determine measurement accuracy on the basis of a predetermined reference value and measured values based on the electrical characteristic measured using the sample for use in electrical characteristic measurement.

Abstract: To an electrical characteristic measuring device that further improves the accuracy of measurement of an electrical characteristic of a blood sample. Provided is an electrical characteristic measuring device including: a measuring unit configured to measure an electrical characteristic of a blood sample; and an alert generation unit configured to issue an alert signal when an erythrocyte sedimentation rate in the blood sample exceeds a prescribed standard during measurement of the blood sample.

Abstract: A blood state analysis device (1) that analyzes a state of a blood sample, as used for clotting time testing, said blood sample comprising a plasma and at least one reagent, including a correction unit (11) configured to correct a measured blood coagulation evaluation result of the blood sample based on a relation between reference concentrations of the at least one reagent in plasma and reference blood coagulation evaluation results, the at least one reagent is an anticoagulation treatment releasing agent, a coagulation activator, an anticoagulant, a platelet activator, an antiplatelet drug, or a combination thereof and is present in the blood sample. For instance, such device (1) allows to correct blood clotting time results with respect to concentrations of an anti-coagulant drug present in the blood sample.